Expression and clinical significance of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma

doi:10.13418/j.issn.1001-165x.2022.5.08

PDF(4524 KB)

Chinese Journal of Clinical Anatomy ›› 2022, Vol. 40 ›› Issue (5) : 541-547. DOI: 10.13418/j.issn.1001-165x.2022.5.08

Expression and clinical significance of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma

Cao Li^1,2, Chen Peng², Li Dingchang², Dong Guanglong²*

Author information +

History +

Abstract

Objective To study the expression of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma and adjacent tissues and analyze their relationship with relevant clinicopathological data, and explore their occurrence and development in colorectal adenocarcinoma and the possible role and clinical significance. Methods Immunohistochemistry was used to detect the expression of p-mTOR, p-4EBP1 and p-S6K1 in 60 cases of colorectal adenocarcinoma tissues and 40 cases of adjacent normal tissues, compare the differences of each group, and analyze their relationship with relevant clinicopathological characteristics. The positive rate correlation analysis was performed by Spearman correlation analysis, and the test level α=0.05. Results The expression levels of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma tissues were higher than those in adjacent tissues on average, with statistically significant differences (P<0.05). The expression of p-mTOR was related to the stage of patients with lymph node metastasis, TNM stage and differentiation degree (P<0.05). The expression of p-S6K1 was related to the TNM stage and differentiation degree of the patient (P<0.05). The expression of p-mTOR and p-4EBP1 in colorectal adenocarcinoma tissue has a certain positive correlation (P<0.05), and the expression of p-mTOR and p-S6K1 in colorectal adenocarcinoma tissue has a significant positive correlation (P<0.05). Conclusions The overexpression of p-mTOR, p-4EBP1 and p-S6K1 in the mucosal tissue of colorectal adenocarcinoma may be one of the important mechanisms for the occurrence of colorectal adenocarcinoma. These three phosphorylated proteins may be related to the occurrence and development of colorectal adenocarcinoma.

Key words

Nasopharyngeal carcinoma; / / Drug resistance; / / Micro RNA; / Cisplatin; / Cyclin protein

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Cao Li, Chen Peng, Li Dingchang, Dong Guanglong. Expression and clinical significance of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma[J]. Chinese Journal of Clinical Anatomy. 2022, 40(5): 541-547 https://doi.org/10.13418/j.issn.1001-165x.2022.5.08

References

[1] 中华人民共和国国家卫生健康委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2020年版)[J]. 中国实用外科杂志, 2020, 40(6): 601-625. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.01.
[2] 汤国辉, 贺修胜. 结直肠癌相关长链非编码RNA的研究进展[J]. 中南医学科学杂志, 2018, 46(3): 241-246. DOI: 10.15972/j.cnki.43-1509/r.2018.03.004.
[3] Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism[J]. Cell, 2006, 124(3): 471-484. DOI: 10.1016/j.cell. 2006. 01.016.
[4] Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update[J]. Oncotarget, 2014, 5(1): 49-66. DOI: 10.18632/oncotarget. 1548.
[5] Zhang YJ, Dai Q, Sun DF, et al. mTOR signaling patnway is a target for the treatment of colorectal cancer[J]. Ann Surg Oncol, 2009, 16(9): 2617-2628. DOI: 10.1245/s10434-009-0555-9.
[6] Zhu Y, Jiang HG, Chen ZH, et al. Short-term efficacy of laparoscopic treatment for colorectal cancer in patients with schistosomiasis japonica[J]. Gastroenterol Res Pract, 2016, 2016: 8357025. DOI: 10.1155/2016/8357025.
[7] O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptortyrosine kinase signaling and activates Akt[J]. Cancer Res, 2006, 66(3): 1500-1508. DOI: 10.1158/0008-5472.CAN-05-2925.
[8] Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel classⅠPI3K/mTOR kinase inhhibitor with robust activity in cancer models driven by the PI3K pathway[J]. Mol Cancer Ther, 2011, 10(12): 2426-2436. DOI: 10.1158/1535-7163.MCT-11-0446.
[9] Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity[J]. Mol Cancer Ther, 2008, 7(7): 1851-1863. DOI: 10.1158/1535-7163.MCT-08-0017.
[10]Dobbelstein M, Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development[J]. Nat Rev Drug Discov, 2014, 13(3): 179-196. DOI: 10.1038/nrd4201.
[11] Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth[J]. Nature, 2006, 441(7092): 424-430. DOI: 10.1038/nature04869.
[12] Hay N, Sonenberg N. Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18(16): 1926-1945. DOI: 10.1101/gad.1212704.
[13] Beca F, Andre R, Martins DR, et al. p-mTOR expression is associated with better prognosis in luminal breast carcinoma[J]. J Clin Pathol, 2014, 67(11): 961-967. DOI: 10.1136/jclinpath-2014-202320.
[14] Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: Mtor, PTEN, STK11, RPKAA1, PRKAG2, TSC1, PI3K, and Akt1[J]. Gareinogenesis, 2010, 39(1): 1604-1611. DOI: 10.1093/carcin/bgq142.
[15] 王茜, 时延龙, 毕经旺. p-mTOR与HIF-1α在结直肠癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2015, 22(6): 779-784. DOI: 10.3872/j.issn.1007-385X.2015.06.017.
[16] 赵长林, 胡芳娟, 曹红霞, 等. 直肠癌组织中mTOR和VEGF的表达与侵袭转移及预后的关系[J]. 临床肿瘤学杂志, 2012, 17(10): 899-903. DOI: 10.3969/j.issn.1009-0460.2012.10.008.
[17] 张毅, 张甘露, 王俊红, 等. 直肠癌组织Akt-mTOR蛋白表达与临床病理因素相关性分析[J]. 中华肿瘤防治杂志, 2013, 20(4): 296-300. DOI:CNKI:SUN:LCZL.0.2012-10-008.
[18] West MG, Stoneley M, Willis AE, et al.Translation induction of the c-myc oncogene via activation of the FRAP/TOR signaling pathway[J]. Oncogene, 1998, 17(6): 769-780. DOI: 10.1038/sj.onc.1201990.
[19] Populo H, Soares P, Faustino A, et al. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics[J]. Pigment Cell Melanoma Res, 2011, 24(1): 254-257. DOI: 10.1111/j.1755-148X.2010.00796.x.
[20] No JH, Jeon YT, Park IA, et al. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer[J]. Gynecol Oncol,2011, 121(1):8-12. DOI: 10.1016/j.ygyno. 2010. 12.364.